I got several reader questions this week about a new recommendation from Dave Lashmet at Stansberry — it looks like this was issued as a recommendation for regular Stansberry Investment Advisory subscribers, not one of Lashmet’s more expensive biotech-focused newsletters, and it’s very light on clues… but let’s see if we can give you anything […]
Articles
[ed note: Michael Jorrin, who I like call “Doc Gumshoe,” is a longtime medical writer who shares his thoughts with us a couple times a month — his articles are non-financial in nature, his words and opinions are his own, and you can see his bio and his past pieces here. Enjoy!] Indulge me while […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
Everytime I see Doc Gumshoe and Alzheimer on the same line in my mailbox I hope it will be about AC Immune (ACIU). Maybe...
$ACIU: A new biotech IPO stock debuted last Friday, September 23: AC Immune, based in Switzerland, is a clinical-stag...
Two biotech IPOs this week might be of some interest. I've personally not been participating in the biotech IPO market b...
Krystyna: I know of AC Immune. My truthful feeling is that its clinical programs are also-rans. Little distinguishes th...
Just read that a company called AC Immune has just filed its F-1 paperwork with the U.S. Securities & Exchange Commissio...